title: 8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: the effect of chemotherapy.
abstract: OBJECTIVE
  The aim of the study was to evaluate the exhaled breath condensate (EBC) levels of a valid oxidative stress marker, 8-isoprostane, before and after chemotherapy, in patients with non small cell lung cancer (NSCLC) in correlation with the extent of the disease and response to treatment.
  
  
  METHODS
  Forty-five patients with inoperable NSCLC were initially enrolled in the study. Twenty-nine of them were finally evaluated in regards to 8-isoprostane levels in EBC before and after chemotherapy.
  
  
  RESULTS
  8-Isoprostane levels were significantly lower after chemotherapy (p=0.014). Further analysis showed that the differences were mainly attributed: a) to the extent of the disease, with patients diagnosed with up to locally advanced disease (stages IB-IIIB) having significantly lower EBC 8-isoprostane levels post-chemotherapy (p=0.031); and b) to the response to treatment, with patients evaluated with partial response to treatment having significantly lower EBC 8-isoprostane levels post-chemotherapy (p=0.02).
  
  
  CONCLUSIONS
  In this prospective study, we showed that 8-isoprostane might represent a biomarker in NSCLC, reflecting both response to chemotherapy, as well as the extent of the disease.
authors.affiliation: Oncology Unit GPP, University of Athens Medical School, Sotiria General Hospital, Athens, Greece dimitrios.stathopoulos@gmail.com.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Stathopoulos
authors.affiliation: Second Respiratory Medicine Department, University of Athens Medical School, Attikon University Hospital, Athens, Greece.
authors.forename: Stelios
authors.initials: S
authors.lastname: Loukides
authors.affiliation: Oncology Unit GPP, University of Athens Medical School, Sotiria General Hospital, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Syrigos
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D045853:Exhalation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018384:Oxidative Stress; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost
keywords: 8-isoprostane; Lung cancer; chemotherapy; exhaled breath condensate